# Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

> **NCT02055274** · PHASE1 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 39 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** LY03003
- **DRUG:** Neupro

## Key facts

- **NCT ID:** NCT02055274
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055274, "Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02055274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*